Skip to main content

Table 1 FBPase expression in cancers (listed in alphabetical order)

From: Targeting FBPase is an emerging novel approach for cancer therapy

Type of cancer FBPase expression Change in expression over disease progression Prognostic significance Reference(s)
Breast cancer Lower in animal model, human breast cancer [74,75,76], basal-like breast cancer cell lines [20], triple-negative breast cancer but not in luminal cell lines [19] and brain metastatic cells [21]. Data mining shown FBP1 over-expression were common in breast cancer irrespective of histological type in cell lines and human breast cancer [20] Expression inhibited tumorigenicity in vitro and tumor-formation in vivo [20, 22] but promoted the growth of brain metastasis [21]. FBP1 expression associated with nuclear grade and tumor stage [18] Loss of FBP1 expression associated with poor survival [18, 20, 22]. But data mining shown no correlation between FBP1 and prognosis in triple-negative breast cancer [20] [18,19,20,21,22, 74,75,76]
Colon cancer Lower in cancer cell lines and in human colon cancer [17] Overexpression reduced cancer cell colony formation and inhibited the growth of cancer cells [17]   [17]
Gastric cancer Downregulated in gastric cancer cell lines and gastric carcinomas [17, 25, 26] Overexpression inhibited proliferation inhibition in vitro as well as xenograft tumor growth in vivo [25, 26] Absent or low FBP2 expression correlated with poor survival [25] [17, 25, 26]
Liver cancer Decreased in 3-methyl-4-dimethyl aminoazobenzene (3MeDAB) induced [77] and choline-deficient diet-induced hepatocellular carcinoma model [78]; Decreased in most human liver cancer cell lines [14, 17] and in human hepatocellular carcinoma [15,16,17, 77, 79,80,81,82] Low expression correlated with highly malignant phenotype, including large tumor size, poor differentiation, advanced tumor stage [15, 80,81,82], vascular cell invasion and high pathological grade [14] Loss of FBP1 expression associated with poor overall survival and higher tumor recurrence rates [14, 15, 79, 81, 82] [14,15,16,17, 77,78,79,80,81,82]
Lung cancer Loss in lung cancer cells [12, 13] and in human lung cancer tissues [13, 83, 84] Forced expression inhibited tumorigenesis and invasion in lung cancer cells [12, 13] and cancer progression in human lung cancer [13] Low FBP1 expression correlated with poor overall survival [13] [12, 13, 83, 84]
Pancreatic cancer Lower in pancreatic cancer tissues [27, 28]   FBP1 expression inversely correlated with tumor grades and prognosis [27, 28] [27, 28]
Renal carcinoma Ubiquitous loss in clear cell renal cell carcinoma [23, 24, 85, 86] FBP1 expression in several renal cancer cell lines inhibited their growth. Suppression of FBP1 correlated with advanced tumour stage [24]. But no correlation was found between clinicopathological factors, including age, gender, T stage, Fuhrman grade and expression of FBP1 expression in another study [23] Suppression correlated with worse patient prognosis [24] [23, 24, 85, 86]
Small intestinal neuroendocrine tumour Comprehensive integrated genomic analysis shown epigenetically dysregulation [87]    [87]